ERBB2 and carcinoma: Seven patients received either targeted treatment for HER2 positive carcinoma (trastuzumab (n = 3); zanidatamab (n = 1)) or immune checkpoint inhibitors (ICI) (nivolumab (n = 2); pembrolizumab (n = 1)).